Inogen Inc. (INGN) Receives Average Recommendation of “Buy” from Analysts
Inogen Inc. (NASDAQ:INGN) has been assigned an average recommendation of “Buy” from the six analysts that are currently covering the firm. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $58.00.
A number of equities analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $67.00 price objective for the company in a research report on Tuesday, October 4th. JPMorgan Chase & Co. began coverage on shares of Inogen in a research report on Wednesday, July 13th. They issued an “overweight” rating for the company. Stifel Nicolaus cut shares of Inogen from a “buy” rating to a “hold” rating in a research report on Friday, August 5th. They noted that the move was a valuation call. Finally, Needham & Company LLC restated a “strong-buy” rating and issued a $64.00 price target (up from $58.00) on shares of Inogen in a research report on Sunday, August 7th.
In other news, CEO Raymond Huggenberger sold 20,747 shares of the company’s stock in a transaction on Monday, August 15th. The shares were sold at an average price of $57.48, for a total value of $1,192,537.56. Following the sale, the chief executive officer now directly owns 27,555 shares of the company’s stock, valued at approximately $1,583,861.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Matt Scribner sold 4,551 shares of the company’s stock in a transaction on Wednesday, October 12th. The shares were sold at an average price of $59.45, for a total transaction of $270,556.95. Following the completion of the sale, the executive vice president now directly owns 6,884 shares in the company, valued at $409,253.80. The disclosure for this sale can be found here. 5.18% of the stock is currently owned by insiders.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/inogen-inc-ingn-receives-average-recommendation-of-buy-from-analysts.html
Several large investors have recently bought and sold shares of INGN. TIAA CREF Investment Management LLC raised its stake in Inogen by 0.9% in the first quarter. TIAA CREF Investment Management LLC now owns 100,661 shares of the medical technology company’s stock worth $4,528,000 after buying an additional 940 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its stake in Inogen by 66.7% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 6,000 shares of the medical technology company’s stock worth $301,000 after buying an additional 2,400 shares in the last quarter. Bayesian Capital Management LP purchased a new stake in Inogen during the first quarter worth approximately $238,000. Nationwide Fund Advisors raised its stake in Inogen by 62.3% in the second quarter. Nationwide Fund Advisors now owns 77,139 shares of the medical technology company’s stock worth $3,865,000 after buying an additional 29,597 shares in the last quarter. Finally, Bogle Investment Management L P DE purchased a new stake in Inogen during the first quarter worth approximately $861,000.
Shares of Inogen (NASDAQ:INGN) traded up 2.66% during midday trading on Tuesday, hitting $57.87. 68,791 shares of the company were exchanged. Inogen has a one year low of $28.81 and a one year high of $61.87. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of 85.10 and a beta of 0.88. The firm’s 50 day moving average price is $59.13 and its 200 day moving average price is $52.30.
Inogen (NASDAQ:INGN) last released its quarterly earnings data on Thursday, August 4th. The medical technology company reported $0.25 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.05. The business earned $54.57 million during the quarter, compared to analysts’ expectations of $52.44 million. Inogen had a net margin of 7.86% and a return on equity of 9.50%. The firm’s quarterly revenue was up 23.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.17 EPS. Analysts forecast that Inogen will post $0.63 EPS for the current fiscal year.
Inogen, Inc is a medical technology company. The Company is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or seven pounds.
Receive News & Ratings for Inogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.